You just read:

LEO Pharma Receives Marketing Authorisation for Kyntheum® (Brodalumab), a New Biologic for the Treatment of Moderate-to-Severe Plaque Psoriasis in the European Union

News provided by

LEO Pharma A/S

Jul 20, 2017, 03:00 ET